Entrada CEO sells 8,724 shares to cover taxes

Entrada Therapeutics’ CEO reported a mandatory sell-to-cover tax-withholding share disposition, with overall holdings remaining above half a million shares.

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) director and CEO Dipal Doshi reported a Form 4 transaction involving 8,724 shares of common stock on September 2, 2026. The shares were disposed of at a weighted average price of $7.1439 under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations and did not represent a discretionary trade. After this tax-withholding disposition, Doshi directly holds 517,290 shares of Entrada Therapeutics common stock.

Insider Trade Summary

Tax Withholding: 8,724 shares

Tax Withholding 1 txn

Insider Doshi Dipal

Role CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1, F2	8,724	$7.1439	$62K

Holdings After Transaction: Common Stock — 517,290 shares (Direct)

Footnotes (2)

1. F1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares disposed for tax withholding: 8,724 shares Weighted average sale price: $7.1439 per share Sale price range: $6.97 to $7.34 per share +1 more

4 metrics

Shares disposed for tax withholding 8,724 shares Mandatory sell-to-cover transaction on September 2, 2026

Weighted average sale price $7.1439 per share Tax-withholding disposition of 8,724 shares

Sale price range $6.97 to $7.34 per share Multiple trades comprising the reported weighted average price

Shares held after transaction 517,290 shares Direct holdings of CEO Dipal Doshi after September 2, 2026 transaction

Key Terms

sell-to-cover, mandatory sell-to-cover provision, weighted average price, statutory tax withholding obligations

4 terms

sell-to-cover financial

"pursuant to a mandatory sell-to-cover provision in the award agreement"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

mandatory sell-to-cover provision financial

"pursuant to a mandatory sell-to-cover provision in the award agreement"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

statutory tax withholding obligations financial

"required to cover minimum statutory tax withholding obligations."

FAQ

What insider transaction did TRDA’s CEO Dipal Doshi report on this Form 4?

Dipal Doshi reported a disposition of 8,724 shares of Entrada Therapeutics common stock on September 2, 2026, executed as a mandatory sell-to-cover transaction to satisfy minimum statutory tax withholding obligations related to an equity award.

Was the TRDA Form 4 transaction a discretionary sale by the CEO?

No. The filing states the shares were automatically sold by the company under a mandatory sell-to-cover provision in the award agreement to cover tax withholding, and that the sale does not represent a discretionary trade by Dipal Doshi.

How many TRDA shares does CEO Dipal Doshi hold after the reported transaction?

After the reported tax-withholding disposition, Dipal Doshi directly holds 517,290 shares of Entrada Therapeutics common stock, as disclosed in the Form 4 following the September 2, 2026 transaction.

At what price were the TRDA shares sold in the CEO’s tax-withholding transaction?

The Form 4 reports a weighted average price of $7.1439 per share. A footnote explains the shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive.

Was the TRDA CEO’s Form 4 transaction made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, and the footnotes describe the sale as pursuant to a mandatory sell-to-cover provision, not as a Rule 10b5-1 trading plan.

What is the nature of the code F transaction reported for TRDA’s CEO?

The transaction is coded “F,” described as payment of tax liability by delivering or withholding securities. The filing states the company automatically sold the 8,724 shares to cover minimum statutory tax withholding obligations tied to an equity award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:24 PM Accepted by SEC EDGAR 09/03/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doshi Dipal

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		F		8,724(1)	D	$7.1439(2)	517,290	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)